Viridian Therapeutics 公认会计原则每股收益 - 0.34 美元，超出 0.68 美元，收入为 7057 万美元

* Viridian Therapeutics 新闻稿 [https://seekingalpha.com/pr/20293955-viridian-therapeutics-reports-third-quarter-2025-financial-results-and-highlights-recent] (VRDN [https://seekingalpha.com/symbol/VRDN])：第三季度 GAAP 每股收益为 - 0.34 美元，比 0.68 美元高出 0.68 美元。
* 收入为 7057 万美元。

有关 VIRIDIAN 疗法的更多信息

* Viridian Therapeutics：甲状腺眼病的去风险领导力 [https://seekingalpha.com/article/4826195-viridian-therapeutics-de-risked-leadership-in-tropical-eye-disease]
* Viridian Therapeutics 定价 2.51 亿美元股票发行 [https://seekingalpha.com/news/4506468-viridian-therapeutics-prices-251m-share-offering]
* Viridian Therapeutics 宣布拟议承销公开发行 [https://seekingalpha.com/news/4506331-viridian-therapeutics-announces-proposed-underwriting-public-offering]
* Seeking Alpha 对 Viridian Therapeutics 的定量评级 [https://seekingalpha.com/symbol/VRDN/ ratings/quant- ratings]
* Viridian Therapeutics 的历史盈利数据 [https://seekingalpha.com/symbol/VRDN/earnings]